ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer

Fujiwara K., Vergote I. B., Sehouli J., Salutari V., Zola P., Madry R., ...More

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 22 - 24 November 2019, vol.30, (Summary Text) identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 30
  • City: Singapore
  • Country: Singapore
  • Istanbul University Affiliated: No